Bond, D J
Silveira, L E
MacMillan, E L
Torres, I J
Lang, D J
Su, W
Honer, W G
Lam, R W
Yatham, L N
Article History
Received: 14 August 2016
Revised: 14 November 2016
Accepted: 15 January 2017
First Online: 28 March 2017
Competing interests
: Dr Bond has received speaking/consulting fees or research grants from AstraZeneca, Bristol Myers Squibb, the Canadian Institutes of Health Research (CIHR), the Canadian Network for Mood and Anxiety Treatments (CANMAT), the Canadian Psychiatric Association (CPA), Janssen-Ortho, Myriad Genetics, Otsuka, Pfizer, Sunovion and the University of British Columbia (UBC) Institute of Mental Health/Coast Capital Depression Research Fund. Dr Torres has received speaking/consulting fees or research grants from CIHR, Lundbeck Canada and Sumitomo Dainippon. Dr Honer has been on advisory boards for In Silico, Otsuka/Lundbeck, Roche and Eli Lily. He was additionally supported by the UBC Jack Bell Chair in Schizophrenia. Dr Lam has been on speaker/advisory boards for, or has received research support from AstraZeneca, Bristol Myers Squibb, CANMAT, CPA, CPA Foundation, CIHR, Eli Lilly, Litebook Company, Lundbeck, Lundbeck Institute, Merck, Mochida, Pfizer, Servier, St Jude Medical, UBC Institute of Mental Health/Coast Capital Depression Research Fund, Takeda and Wyeth. Dr Yatham has been on speaker/advisory boards for, or has received research support from AstraZeneca, Bristol Myers Squibb, CANMAT, CIHR, Eli Lilly, GlaxoSmithKline, Janssen, the Michael Smith Foundation for Health Research, Pfizer, Servier and the Stanley Foundation. The remaining authors declare no conflict of interest.